Last reviewed · How we verify
NCT03875534
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
trial in Achondroplasia in 260 participants. Completed in 12 January 2024.
12 January 2024
Quick facts
| Lead sponsor | Ascendis Pharma A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 260 |
| Start date | 19 June 2019 |
| Primary completion | 12 January 2024 |
| Estimated completion | 12 January 2024 |
| Sites | 35 locations across Denmark, France, Italy, New Zealand, Austria, Ireland, United Kingdom, Germany |
Conditions studied
- Achondroplasia — all drugs for Achondroplasia →
Sponsor
Ascendis Pharma A/S — full company profile →
Who can join
Adults 0 to 8, any sex, with Achondroplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natural history study and no study medication will be administered.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood.
Kim HY, Ko JM. · · 2022 · cited 10× · PMID 35793999 · DOI 10.6065/apem.2244114.057 -
Longitudinal Observation of Children with Achondroplasia: Findings from a Global Natural History Study (ACHieve).
McDonnell C, Hove HB, Irving M, White KK, et al · · 2026 · PMID 41505353 · DOI 10.1159/000550169 -
Design and Baseline Demographics of a Five-Year, Multi-National Observational Cohort Study of Children With Achondroplasia (ACHieve Study)
Ward L, de Bergua J, Robinson M, Zhang Y, et al · · 2021
Verify or expand the search:
- PubMed search for NCT03875534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Achondroplasia
Currently open trials in the same condition.
- NCT07301463 — A Study in Children With Achondroplasia · recruiting
- NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
- NCT05328050 — Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) · recruiting
Other Ascendis Pharma A/S trials
Trials by the same sponsor.
- NCT05980598 — TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carci · Phase 2 · terminated
- NCT04085523 — A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Pr · Phase 2 · completed
- NCT04009291 — A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism · Phase 2 · completed
- NCT03344458 — A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03875534 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ascendis Pharma A/S
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03875534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing